Genetic Architecture of Supraventricular Arrhythmias from SVTs and Atrial Fibrillation to Inherited Channelopathies: Implications for Diagnosis, Risk Stratification, and Personalised Therapy

Supraventricular tachycardias (SVTs) and atrial fibrillation (AFib) represent highly prevalent cardiac arrhythmias that carry significant global health and economic burdens. Traditionally, clinical management has relied on electrophysiological evaluations and symptom-rhythm correlation. However, rapid advancements in genomic research have begun to reshape our understanding, highlighting heritable factors in arrhythmia predisposition, recurrence, and patient-specific therapeutic responses.While next-generation sequencing has unveiled numerous associated genetic variants, translating these molecular insights into everyday clinical practice remains a major hurdle. Progress is slowed by incomplete genotype-phenotype correlation, limited functional validation, and a lack of systematic clinical implementation frameworks. Closing this gap is urgent.This Research Topic aims to bridge the gap between genetic discoveries and the clinical care of patients with supraventricular arrhythmias and inherited conduction-system disorders. The scope encompasses the genetic architecture of SVTs, Atrial Fibrillation (AFib), and the supraventricular phenotypes of inherited channelopathies (such as Long QT, Brugada, and CPVT), bringing together a broad and active research community around a shared translational challenge.We welcome submissions drawing from human cohorts, translational models, or advanced in vitro systems. Shorter formats (Mini Reviews, Perspectives, and clinical Case Reports/Series) are encouraged alongside full Original Research.We welcome submissions addressing, but not limited to:• Discovery and functional validation of novel genes and variants related to SVTs, AFib, and inherited channelopathies;• Prognostic implications of genetic markers in recurrence risk, post-ablation outcomes, and pharmacotherapy;• Genotype-phenotype correlations and the integration of genomic data in risk stratification;• Genotype-guided pharmacological and ablation therapies;• Innovations and economic considerations in clinical genetic testing for cardiac arrhythmias;• Ethical and practical frameworks for implementing genomic medicine in arrhythmia care.Studies strictly limited to general epidemiology or non-genetic risk factors will not be prioritised. Topic editors: Martin Ezeani, Mohammad Alasti Source: https://www.frontiersin.org/research-topics/85896/genetic-architecture-of-supraventricular-arrhythmias-from-svts-and-atrial-fibrillation-to-inherited-channelopathies-implications-for-diagnosis-risk-stratification-and-personalised-therapy